- Home
- IFRX vs STHO Comparison
IFRX vs STHO Comparison
Compare IFRX & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- STHO
- Stock Information
- Founded
- IFRX 2007
- STHO N/A
- Country
- IFRX Germany
- STHO United States
- Employees
- IFRX N/A
- STHO N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- STHO Real Estate
- Sector
- IFRX Health Care
- STHO Real Estate
- Exchange
- IFRX Nasdaq
- STHO Nasdaq
- Market Cap
- IFRX 117.8M
- STHO 117.1M
- IPO Year
- IFRX 2017
- STHO N/A
- Fundamental
- Price
- IFRX $1.05
- STHO $7.98
- Analyst Decision
- IFRX Strong Buy
- STHO
- Analyst Count
- IFRX 2
- STHO 0
- Target Price
- IFRX $9.00
- STHO N/A
- AVG Volume (30 Days)
- IFRX 356.5K
- STHO 115.2K
- Earning Date
- IFRX 03-20-2025
- STHO 05-09-2025
- Dividend Yield
- IFRX N/A
- STHO N/A
- EPS Growth
- IFRX N/A
- STHO N/A
- EPS
- IFRX N/A
- STHO N/A
- Revenue
- IFRX $171,642.00
- STHO $113,297,000.00
- Revenue This Year
- IFRX $381.73
- STHO N/A
- Revenue Next Year
- IFRX $2,277.23
- STHO N/A
- P/E Ratio
- IFRX N/A
- STHO N/A
- Revenue Growth
- IFRX 162.79
- STHO N/A
- 52 Week Low
- IFRX $1.01
- STHO $7.96
- 52 Week High
- IFRX $2.82
- STHO $14.50
- Technical
- Relative Strength Index (RSI)
- IFRX 31.57
- STHO 41.71
- Support Level
- IFRX $1.16
- STHO $7.97
- Resistance Level
- IFRX $1.30
- STHO $8.91
- Average True Range (ATR)
- IFRX 0.12
- STHO 0.35
- MACD
- IFRX 0.02
- STHO -0.00
- Stochastic Oscillator
- IFRX 9.76
- STHO 1.07
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.